Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The
surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected
with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.
Phase:
Phase 4
Details
Lead Sponsor:
Baqiyatallah Medical Sciences University
Collaborators:
Baqiyatallah Research Center for Gastroenterology and Liver Diseases Guilan Research Center for Gastroenterology and Liver Diseases Guilan University of Medical Sciences Iran University of Medical Sciences Research Center for Gastroenterology and Liver Disease, Iran University of Medical Sciences, Firoozgar Hospital Shahid Beheshti University of Medical Sciences Tabriz Research Center for Gastroenterology and Liver Diseases Tehran Hepatitis Center